| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2694fd4c63bfaa7635c0c1ff05d8af5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10332
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16632
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24132 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-763
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-17 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-763
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 |
| filingDate |
2019-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6ca10a4c508f18831eb63712f6ff688
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc1d4e90f83b4a61b154227dc78c40e4 |
| publicationDate |
2019-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20190103979-A |
| titleOfInvention |
Pharmaceutical composition for preventing or treating cancer comprising oncolytic virus and hydroxyurea |
| abstract |
The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising an anticancer virus and hydroxyurea as an active ingredient. The pharmaceutical composition for preventing or treating cancer comprising the anticancer virus and hydroxyurea of the present invention as an active ingredient has better tumor suppression effect than the conventional anticancer virus, and can kill cancer cells resistant to the anticancer virus. have. Therefore, the pharmaceutical composition for preventing or treating cancer of the present invention can be usefully used to treat cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021162525-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021040064-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102216319-B1 |
| priorityDate |
2018-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |